These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29902695)

  • 1. Therapeutic strategies for targeting neurodegenerative protein misfolding disorders.
    Scannevin RH
    Curr Opin Chem Biol; 2018 Jun; 44():66-74. PubMed ID: 29902695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics.
    Gandhi J; Antonelli AC; Afridi A; Vatsia S; Joshi G; Romanov V; Murray IVJ; Khan SA
    Rev Neurosci; 2019 May; 30(4):339-358. PubMed ID: 30742586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity.
    Thellung S; Corsaro A; Nizzari M; Barbieri F; Florio T
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review.
    Khanam H; Ali A; Asif M; Shamsuzzaman
    Eur J Med Chem; 2016 Nov; 124():1121-1141. PubMed ID: 27597727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?
    Bayer TA
    Eur Neuropsychopharmacol; 2015 May; 25(5):713-24. PubMed ID: 23642796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.
    Maiti P; Manna J; Veleri S; Frautschy S
    Biomed Res Int; 2014; 2014():495091. PubMed ID: 25386560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding.
    Ho L; Pasinetti GM
    Expert Rev Proteomics; 2010 Aug; 7(4):579-89. PubMed ID: 20653511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
    Victoria GS; Zurzolo C
    J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review on protein misfolding, aggregation and strategies to prevent related ailments.
    Shamsi TN; Athar T; Parveen R; Fatima S
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):993-1000. PubMed ID: 28743576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Walking the tightrope: proteostasis and neurodegenerative disease.
    Yerbury JJ; Ooi L; Dillin A; Saunders DN; Hatters DM; Beart PM; Cashman NR; Wilson MR; Ecroyd H
    J Neurochem; 2016 May; 137(4):489-505. PubMed ID: 26872075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer and its applications in neurodegenerative diseases.
    Qu J; Yu S; Zheng Y; Zheng Y; Yang H; Zhang J
    Cell Mol Life Sci; 2017 Feb; 74(4):683-695. PubMed ID: 27563707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis of protein homeostasis and aggregation.
    Laskowska E; Kuczyńska-Wiśnik D; Lipińska B
    J Proteomics; 2019 Apr; 198():98-112. PubMed ID: 30529741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein aggregation, misfolding and consequential human neurodegenerative diseases.
    Sami N; Rahman S; Kumar V; Zaidi S; Islam A; Ali S; Ahmad F; Hassan MI
    Int J Neurosci; 2017 Nov; 127(11):1047-1057. PubMed ID: 28110595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential roles of natural products in the targeting of proteinopathic neurodegenerative diseases.
    Dash R; Jahan I; Ali MC; Mitra S; Munni YA; Timalsina B; Hannan MA; Moon IS
    Neurochem Int; 2021 May; 145():105011. PubMed ID: 33711400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering enhanced protein disaggregases for neurodegenerative disease.
    Jackrel ME; Shorter J
    Prion; 2015; 9(2):90-109. PubMed ID: 25738979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing the power of yeast to unravel the molecular basis of neurodegeneration.
    Tenreiro S; Munder MC; Alberti S; Outeiro TF
    J Neurochem; 2013 Nov; 127(4):438-52. PubMed ID: 23600759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleic acid aptamers for neurodegenerative diseases.
    Bouvier-Müller A; Ducongé F
    Biochimie; 2018 Feb; 145():73-83. PubMed ID: 29104136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis.
    Mulligan VK; Chakrabartty A
    Proteins; 2013 Aug; 81(8):1285-303. PubMed ID: 23508986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.